Litcius/Paper detail

Deacetylation of Glutaminase by HDAC4 contributes to Lung Cancer Tumorigenesis

Tao Wang, Zhuo Lü, Tianyu Han, Yanan Wang, Mingxi Gan, Jianbin Wang

2022International Journal of Biological Sciences26 citationsDOIOpen Access PDF

Abstract

Inhibiting cancer metabolism via glutaminase (GAC) is a promising strategy to disrupt tumor progression. However, mechanism regarding GAC acetylation remains mostly unknown. In this study, we demonstrate that lysine acetylation is a vital post-translational modification that inhibits GAC activity in non-small cell lung cancer (NSCLC). We identify that Lys311 is the key acetylation site on GAC, which is deacetylated by HDAC4, a class II deacetylase. Lys311 acetylation stimulates the interaction between GAC and TRIM21, an E3 ubiquitin ligase of the tripartite motif (TRIM) family, therefore promoting GAC K63-linked ubiquitination and inhibiting GAC activity. Furthermore, GAC K311Q mutation in A549 cells decreases cell proliferation and alleviates tumor malignancy. Our findings reveal a novel mechanism of GAC regulation by acetylation and ubiquitination that participates in non-small cell lung cancer tumorigenesis.

Topics & Concepts

AcetylationUbiquitinCarcinogenesisUbiquitin ligaseCancer researchHDAC4ChemistryGlutaminaseHistone deacetylaseResveratrolLung cancerLysineBiologyBiochemistryHistoneGlutamineMedicineAmino acidInternal medicineHistone methyltransferaseGeneEpigenetics and DNA MethylationCancer, Hypoxia, and MetabolismHistone Deacetylase Inhibitors Research
Deacetylation of Glutaminase by HDAC4 contributes to Lung Cancer Tumorigenesis | Litcius